🔷 These results support the growing role of immunotherapy-based combinations in earlier hepatocellular carcinoma treatment. Integrating systemic and locoregional therapies may help improve patient outcomes.
🔗 Read more: bit.ly/ONCOnews-07-...
#ONCOnews #OncoAlert #OncEd #LiverCancer #Astrazeneca
🔷 This highlights the growing role of real-world evidence in precision oncology, enabling broader application of HER2-directed therapy across tumor types and informing regulatory decisions in biomarker-defined populations.
🔗 Read more: bit.ly/ONCOnews-31-...
#ONCOnews #OncoAlert #OncEd #Oncology
🔷 Tarlatamab offers a novel treatment approach for patients with limited options in the relapsed ES-SCLC setting. The positive opinion highlights continued progress in expanding targeted therapies for aggressive lung cancers.
🔗 Read more: bit.ly/ONCOnews-30-...
#ONCOnews #OncoAlert #OncEd
🔷 The approval strengthens precision oncology by supporting more personalized treatment decisions in upper gastrointestinal cancers. PD-L1 testing remains a key tool in optimizing therapy selection and improving clinical outcomes.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd
🔷 Relacorilant, a selective glucocorticoid receptor antagonist, enhances chemotherapy activity through cortisol pathway modulation, offering a promising new approach for patients with limited therapeutic alternatives.
🔗 Read more: bit.ly/ONCOnews-27M...
#ONCOnews #OncoAlert #OncEd #FDAApproval
🔷 Fast Track status may support expedited development and regulatory review of TRI-611. This milestone reflects continued progress in expanding targeted therapy options for patients with ALK-driven tumors.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC
🔷 Secondary outcomes included testosterone suppression, overall survival, and safety, with tE2 showing similar castration rates and fewer hot flashes but higher gynecomastia, supporting its potential as an alternative hormonal therapy option.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #Onco
🔷 The combination significantly improved 3-year DFS (86.3% vs 76.2%; HR 0.50; P<0.001), with higher grade 3–4 adverse events (84.1% vs 71.9%); overall survival remains a secondary endpoint under evaluation.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch
🔷 Orphan Drug Designation supports accelerated development in high unmet-need settings, underscoring growing interest in targeted ADC approaches to improve outcomes in this aggressive malignancy.
🔗 Read more: bit.ly/ONCOnews-25-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #LungCancer
🔷 Phase 3 SWOG 1826 data showed significantly improved progression-free survival with nivolumab + AVD (HR 0.42; 58% risk reduction), supporting its role in advancing long-term disease control.
🔗 Read more: bit.ly/ONCOnews-24M...
#ONCOnews #OncoAlert #OncEd #Oncology #Hematology #HodgkinLymphoma
🔷 The combination significantly improved radiographic progression-free survival versus Enzalutamide alone, exceeding the predefined hazard ratio target of 0.63, with consistent benefit across BRCA and non-BRCA subgroups
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd #Prostate
🔷 Relapsed/refractory DLBCL remains a challenging setting with limited durable treatment options for many patients. The Phase III development of HMPL-760 may contribute to expanding targeted therapy strategies in aggressive lymphoma.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd
🔷 Findings from BRIGHT-2 provide important insights into combination therapy approaches for HR+ advanced breast cancer following endocrine progression.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd #BreastCancer #AdvancedBreastCancer #HRPositive #Oncology #CancerResearch
🔗 Read more: bit.ly/ONCOnews-19M...
#ONCOnews #OncoAlert #OncEd #OvarianCancer #CancerResearch #Oncology #PrecisionMedicine #PersonalizedMedicine #CompanionDiagnostics #Biomarkers #TargetedTherapy #CancerCare #OncologyNews #ClinicalTrials #DrugDevelopment #FDAApproval #PharmaNews #MedTech
🔷 In Phase 2/2b studies, the agent improved intraoperative decision-making in 43–45% of cases. If confirmed, this approach could enhance tumor localization and support more complete resections in minimally invasive and robotic surgery.
🔗 Read more: bit.ly/ONCOnews-18M...
#ONCOnews #OncoAlert
🔷 With a median follow-up of 5.5 years, three-year EFS was 59% with zoledronic acid vs 57% without, while OS was 75% in both groups. These results showed no survival benefit from adding zoledronic acid.
🔗 Read more: bit.ly/ONCOnews-16-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch
🔗 Read more: bit.ly/ONCOnews-16-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #CervicalCancer #Immunotherapy #CancerTreatment #ClinicalTrials #OncologyNews #MedicalResearch #PrecisionMedicine #CancerCare #HealthcareInnovation #CancerScience #OncologyCommunity #WomenHealth #Gynecologic
🔷 However, the combination did not improve overall survival (OS) (15.0 vs 17.9 months; HR 1.15) and was associated with higher grade 3–4 adverse events (66.9% vs 38.3%).
🔗 Read more: bit.ly/ONCOnews13-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #Immunotherapy #TargetedTherapy
🔷 84% of patients receiving Romiplostim avoided CIT-related chemotherapy delays or dose reductions vs 36% with placebo (OR 10.16, P<0.001).
🔗 Read more: bit.ly/ONCOnews-12M...
#ONCOnews #OncoAlert #OncEd #Chemotherapy #Thrombocytopenia #ChemotherapyInducedThrombocytopenia #Oncology #Cancer
🔷 If cleared, the system could improve surgical accuracy and potentially reduce the need for repeat procedures. Innovations like this aim to enhance outcomes and support more effective breast-conserving surgery.
🔗 Read more: bit.ly/ONCOnews-12M...
#ONCOnews #OncoAlert #OncEd #BreastCancer #Breast
🔷 Findings highlight how advanced imaging may refine prognosis and guide more personalized treatment strategies in prostate cancer.
🔗 Read more: bit.ly/ONCOnews-11M...
#ONCOnews #OncoAlert #OncEd #ProstateCancer #PSMAPET #Oncology #CancerResearch #CancerImaging #PrecisionMedicine #Urology #Cancer
🔷 The study explores whether this combination strategy can offer improved clinical outcomes compared with standard immunotherapy alone.
🔗 Read more: bit.ly/ONCOnews-11M...
#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC #CancerResearch #Oncology #Immunotherapy #CancerTreatment #ClinicalTrials
🔷 This marks the first positive Phase III trial for the oral CELMoD Mezigdomide, with a safety profile consistent with prior studies.
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
🔗 Read more: bit.ly/ONCOnews09Ma...
#ONCOnews #OncoAlert #OncEd #BreastCancer #TrastuzumabDeruxtecan #AntibodyDrugConjugate #ADC #CancerTreatment #Oncology #OncologyNews
🔷 Approval is based on the Phase III POD1UM-303 trial, where the combination reduced the risk of progression or death by 37% and improved median PFS to 9.3 months vs 7.4 months with chemotherapy alone, with no new safety signals reported.
🔗 Read more: bit.ly/ONCOnews09Ma...
#ONCOnews #OncoAlert
🔷 Development of Giredestrant continues across settings, including evERA in advanced disease (NDA accepted by the FDA) and lidERA in early breast cancer, with submission planned soon.
🔗 Read more: bit.ly/ONCOnews09Ma...
#ONCOnews #OncoAlert #OncEd #BreastCancer #AdvancedBreastCancer #Metastatic
🔷 Based on the MajesTEC-3 trial, this combination brings together a BCMA-targeted bispecific antibody and CD38-directed therapy, offering a novel dual-targeted approach for patients who have received prior lines of therapy.
🔗 Read more: bit.ly/ONCOnews06-M...
#ONCOnews #OncoAlert #OncEd #Oncology
🔷 Based on results from the phase 3 BRUIN CLL-321 trial, this treatment expands options for patients progressing after prior BTK inhibitor therapy, marking a key milestone in hematologic oncology.
🔗 Read more: bit.ly/ONCOnews04-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Cancer
🔷 Based on Phase 3 VERIFY data, if approved, Rusfertide could become a first-in-class therapy, offering a novel treatment approach for patients requiring improved hematocrit control.
🔗 Read more: bit.ly/ONCOnews03-M...
#ONCOnews #OncoAlert #OncEd #BiotechNews #PharmaNews #Oncology #Hematology
🔷 The LITESPARK-022 Phase 3 data suggests added benefit from combining PD-1 blockade with HIF-2α inhibition in the post-nephrectomy setting.
🔗 Read more: bit.ly/ONCOnews02-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #Immunotherapy #TargetedTherapy #RenalCellCarcinoma #KidneyCancer
